TNF-naïve
|
Pain VAS, mean change from baselinea
|
Secukinumab 300 mg
|
−19.7*
|
−20.7**
|
− 20.7*
|
−27.8****
|
− 24.0
|
−30.3
|
−29.6
|
Secukinumab 150 mg
|
−12.8
|
−15.2
|
−21.8*
|
− 25.1***
|
−26.3
|
−28.1
|
−28.3
|
Placebo
|
−8.5
|
−11.3
|
−10.1
|
−11.3
|
–
|
–
|
–
|
SF-36 bodily pain, mean change from baselineb
|
Secukinumab 300 mg
|
–
|
18.4****
|
18.2*
|
23.8****
|
23.9
|
24.4
|
24.2
|
Secukinumab 150 mg
|
–
|
18.9****
|
20.0***
|
25.4****
|
25.7
|
25.8
|
22.2
|
Placebo
|
–
|
5.6
|
7.3
|
8.6
|
–
|
–
|
–
|
EQ-5D-3 L, no pain or discomfortc
|
Secukinumab 300 mg
|
–
|
–
|
–
|
21.5%
|
24.6%
|
28.6%
|
32.8%
|
Secukinumab 150 mg
|
–
|
–
|
–
|
22.2%
|
14.8%
|
20.3%
|
17.0%
|
Placebo
|
–
|
–
|
–
|
6.9%
|
–
|
–
|
–
|
TNF-IR
|
Pain VAS, mean change from baselined
|
Secukinumab 300 mg
|
−13.1**
|
−14.9
|
−16.8**
|
−18.2**
|
−20.7
|
−22.5
|
−19.3
|
Secukinumab 150 mg
|
−14.8*
|
−21.3*
|
−21.2*
|
−21.1*
|
− 20.0
|
−23.9
|
− 20.4
|
Placebo
|
−2.1
|
−5.9
|
−3.4
|
−4.4
|
–
|
–
|
–
|
SF-36 bodily pain, mean change from baselinee
|
Secukinumab 300 mg
|
–
|
15.1
|
18.7*
|
18.3*
|
23.6
|
23.0
|
24.5
|
Secukinumab 150 mg
|
–
|
13.6
|
21.0***
|
17.9*
|
16.0
|
19.0
|
14.0
|
Placebo
|
–
|
7.8
|
5.7
|
5.2
|
–
|
–
|
–
|
EQ-5D-3 L, no pain or discomfortf
|
Secukinumab 300 mg
|
–
|
–
|
–
|
12.5%
|
12.5%
|
15.6%
|
17.2%
|
Secukinumab 150 mg
|
–
|
–
|
–
|
10.8%
|
5.9%
|
20.0%
|
12.5%
|
Placebo
|
–
|
–
|
–
|
3.3%
|
–
|
–
|
–
|